These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38100400)

  • 1. Concerns That May Limit the Utility of Zuranolone.
    Prasad V; Allely D
    JAMA; 2024 Jan; 331(2):105-106. PubMed ID: 38100400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zuranolone: The First FDA-Approved Oral Treatment Option for Postpartum Depression.
    Barnes KN; Vogl CM; Nelson LA
    Ann Pharmacother; 2024 Jul; 58(7):728-734. PubMed ID: 37876133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New depression drug zuranolone one step closer to FDA ruling.
    Carvalho T
    Nat Med; 2023 May; 29(5):1032-1033. PubMed ID: 37041352
    [No Abstract]   [Full Text] [Related]  

  • 4. A Fast-Acting Pill Received Approval for Postpartum Depression-Is It a Game Changer?
    Rubin R
    JAMA; 2023 Sep; 330(10):902-904. PubMed ID: 37610758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zuranolone: First Approval.
    Heo YA
    Drugs; 2023 Nov; 83(16):1559-1567. PubMed ID: 37882942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder.
    Arnaud A; Suthoff E; Stenson K; Werneburg B; Hodgkins P; Bonthapally V; Jonas J; Meyer K; O'Day K
    J Affect Disord; 2021 Apr; 285():112-119. PubMed ID: 33640861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Food and Drug Administration-Approved Treatments for Acute Bipolar Depression: What We Have and What We Need.
    Citrome L
    J Clin Psychopharmacol; 2020; 40(4):334-338. PubMed ID: 32639285
    [No Abstract]   [Full Text] [Related]  

  • 8. New Drugs & Indications for 2017: The Year in Review.
    J Psychosoc Nurs Ment Health Serv; 2018 Jan; 56(1):19. PubMed ID: 29328352
    [No Abstract]   [Full Text] [Related]  

  • 9. Esketamine for Treatment-Resistant Depression - First FDA-Approved Antidepressant in a New Class.
    Kim J; Farchione T; Potter A; Chen Q; Temple R
    N Engl J Med; 2019 Jul; 381(1):1-4. PubMed ID: 31116916
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esketamine for treatment resistant depression.
    Jauhar S; Morrison P
    BMJ; 2019 Sep; 366():l5572. PubMed ID: 31548292
    [No Abstract]   [Full Text] [Related]  

  • 12. Thinking outside the (black) box: antidepressants, suicidality, and research synthesis.
    Greenhouse JB; Kelleher KJ
    Pediatrics; 2005 Jul; 116(1):231-3. PubMed ID: 15995059
    [No Abstract]   [Full Text] [Related]  

  • 13. Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials.
    Preskorn SH
    J Psychiatr Pract; 2021 Mar; 27(2):115-120. PubMed ID: 33656817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zuranolone provides a rapid response without chronic dosing: Response to correspondence by ten Doesschate et al.
    Arnaud A; Bonthapally V
    J Affect Disord; 2022 Mar; 301():445-447. PubMed ID: 35032505
    [No Abstract]   [Full Text] [Related]  

  • 15. Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.
    Roman MW; Wilkinson SM
    Issues Ment Health Nurs; 2014 Dec; 35(12):972-4. PubMed ID: 25426751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Still no evidence for the efficacy of zuranolone beyond two weeks: Response to Arnaud and Bonthapally.
    Ten Doesschate F; van Waarde JA; van Wingen GA
    J Affect Disord; 2022 Sep; 313():149-150. PubMed ID: 35780962
    [No Abstract]   [Full Text] [Related]  

  • 18. Establishing the real cost of depression.
    Sheehan DV
    Manag Care; 2002 Aug; 11(8 Suppl):7-10; discussion 21-5. PubMed ID: 12233202
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies may not provide clear view of antipsychotics.
    Kuehn BM
    JAMA; 2012 Apr; 307(15):1572. PubMed ID: 22511673
    [No Abstract]   [Full Text] [Related]  

  • 20. Evening the score on sex drugs: feminist movement or marketing masquerade?
    Moynihan R
    BMJ; 2014 Oct; 349():g6246. PubMed ID: 25354348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.